Detection of breast carcinoma with an ICG enhanced optical imaging device in breast cancer patients.

Detection of breast carcinoma with an ICG enhanced optical imaging device in breast cancer patients. - ICG enhanced optical imaging in breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33137

Enrollment

Registered

2009-06-15

Start date

2009-09-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer lumpectomy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Women above the age of 21 who have biopsy-proven breast cancer stage I-II who are undergoing lumpectomy

Exclusion criteria

Exclusion criteria: Pregnant women, significant renal, cardiac or pulmonary disease, history of iodine allergy or anaphylactic reactinos to insect bites or medication, presence or history of hyperthyroidism

Design outcomes

Primary

Measure	Time frame
Primary Objective: * Ergonomics and function of the imaging system - the NIRF imaging system should not interfere with the standard lumpectomy procedure and be used safely by the surgeon while detection of ICG takes place. Duration: 1,5 hour clinical procedure	—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results